Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …

Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

11.1. General The treatment strategy for ulcerative colitis [UC] is mainly based on the
severity, distribution [proctitis, left-sided, extensive] 1 and pattern of disease. The latter …

The Real-World Effectiveness and Safety of Vedolizumab for M... : Official journal of the American
College of Gastroenterology | ACG The Real-World Effectiveness and Safety of Vedolizumab for …

Background Selective patient recruitment can produce discrepancies between clinical trial
results and real-world effectiveness. Methods A systematic literature review and meta …

Introduction and objective The therapeutic role of fecal microbiota transplantation in
ulcerative colitis varies across different reports. This study aims to evaluate the long-term …

Background Vedolizumab, a monoclonal antibody targeting the α4β7‐integrin, is effective in
inducing and maintaining clinical remission in Crohn's disease and ulcerative colitis …

Background Vedolizumab [VDZ] is an anti-integrin monoclonal antibody effective in
ulcerative colitis [UC] and Crohn's disease [CD]. Several real-world experience [RWE] …